Freidoon Ghazi, MD
Cardiovascular Disease · Cincinnati, OHNPI 1922098342
Payments from drug & device makers
Across 430 payments — averaging $651.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$207K
- AstraZeneca$34K
- Johnson & Johnson$21K
- Bayer$6K
- Boston Scientific$6K
- Sanofi US Services Inc.$2K
- plus $5K from 30 others
What the payments were for
- Consulting fees$4,9179%
- Speaking & faculty fees$36,85066%
- Travel & lodging$3,4166%
- Food & beverage$10,41319%
- Education$1020%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 81 | $206,705 |
| AstraZeneca | 65 | $33,502 |
| Johnson & Johnson | 81 | $21,312 |
| Bayer | 16 | $5,989 |
| Boston Scientific | 35 | $5,875 |
| Sanofi US Services Inc. | 1 | $2,000 |
| Boehringer Ingelheim | 22 | $643 |
| Abbott | 6 | $580 |
| Amarin Pharma, Inc. | 32 | $573 |
| Amgen | 19 | $304 |
| Merck | 11 | $293 |
| Pfizer | 9 | $282 |
| Actelion Pharmaceuticals US, Inc. | 2 | $245 |
| Daiichi Sankyo Inc. | 9 | $180 |
| Alnylam Pharmaceuticals Inc. | 7 | $168 |
| Edwards Lifesciences | 2 | $167 |
| Cvrx, Inc. | 1 | $164 |
| ZOLL Respicardia, Inc. | 1 | $138 |
| E.r. Squibb & Sons, L.L.C. | 3 | $132 |
| ANI Pharmaceuticals, Inc. | 1 | $125 |
| Abiomed | 1 | $125 |
| Esperion Therapeutics, Inc. | 1 | $111 |
| Lilly USA, LLC | 2 | $94 |
| Scpharmaceuticals Inc. | 4 | $63 |
| Irhythm Technologies, Inc. | 2 | $60 |
| Novo Nordisk | 3 | $53 |
| Vifor Pharma, Inc. | 2 | $36 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $34 |
| Lexicon Pharmaceuticals, Inc. | 2 | $28 |
| Inari Medical, Inc. | 1 | $25 |
| Cook Medical LLC | 1 | $24 |
| Lantheus Medical Imaging, Inc. | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
| Terumo Medical Corporation | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$20,014
- FARXIGA$14,340
- Kerendia$5,516
- Watchman$5,369
- ENTRESTO$703
- UPTRAVI$245
- OPSUMIT$245
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$235
- Barostim Neo System$164
- MitraClip$155
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$151
- remede System$138
- CAMZYOS$125
- PURIFIED CORTROPHIN GEL$125
- Impella$125
- VERQUVO$121
- CARDIOMEMS$121
- BRILINTA$116
- NEXLIZET$111
- NEXLETOL$111
How this compares
$280,111 in reported general payments places this provider in the 95th percentile of 827 cardiovascular disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 132 | $130,714 |
| EntrestoSacubitril/Valsartan | 83 | $94,751 |
| XareltoRivaroxaban | 69 | $72,221 |
| JardianceEmpagliflozin | 82 | $69,021 |
| FarxigaDapagliflozin Propanediol | 65 | $60,910 |
| VascepaIcosapent Ethyl | 60 | $27,185 |
| Repatha SureclickEvolocumab | 13 | $14,799 |
| Metoprolol Succinate | 222 | $2,438 |
| Valsartan | 72 | $2,077 |
| Ranolazine ErRanolazine | 17 | $1,750 |
| Flecainide Acetate | 49 | $1,458 |
| Torsemide | 74 | $875 |
| Spironolactone | 110 | $868 |
| Rosuvastatin Calcium | 56 | $830 |
| Amiodarone Hcl | 32 | $681 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $282 | $130,714132 claims |
| NovartisEntresto | $206,705 | $94,75183 claims |
| Johnson & JohnsonXarelto | $21,312 | $72,22169 claims |
| Boehringer IngelheimJardiance | $643 | $69,02182 claims |
| AstraZenecaFarxiga | $33,502 | $60,91065 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $125 | $2,07772 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 827 cardiovascular disease providers in Ohio.
Other cardiovascular disease in Cincinnati
- Peter EngelCincinnati$1.2M
- Wojciech MazurCincinnati$508K
- Dylan SteenCincinnati$469K
- Kamal ShemisaCincinnati$418K
- Anil VermaCincinnati$195K
- Samir KapadiaCleveland$11.1M
- Steven NissenCleveland$5.3M
- Milind DesaiCleveland$5M
- Abraham LincoffCleveland$3.6M
- Carlos HubbardCleveland$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.